Who shines through biological barriers? – Permexa™ Sodium Caprate

The promise of oral biologics continues to drive innovation across the pharmaceutical industry.  While permeation enhancement remains critical for successful oral peptide and biologic delivery, formulators must also overcome challenges related to powder flowability, tablet robustness, manufacturability, and commercial scale-up.

Ashland permexa™ sodium caprate is a process-engineered permeation enhancer, developed to support formulators and address both oral delivery and manufacturing requirements. Built upon clinically established permeation enhancement technology, permexa™ sodium caprate (C10) supports improved powder flowability, tablet compactibility and robust manufacturability required for scalable oral solid dosage formulation, while maintaining comparable drug absorption enhancement under evaluated conditions.

As the first in a growing Ashland oral biologics platform, permexa™ sodium caprate (C10) is a foundational technology that enables formulators to move beyond proof-of-concept batching, toward robust and scalable tablet forms for peptides and other poorly permeable molecules. This includes the high growth global market for oral GLP-1 agonist programs and formulations evaluating SNAC-alternative delivery approaches.

Permexa™ sodium caprate (C10) enables our customers to accelerate their path of oral solid dosage formulation from development to commercialization, aligned with Ashland formulation expertise, regulatory support, and oral solid dosage capabilities.

Applications

supporting oral delivery applications for peptides, biologics, and other poorly permeable therapeutic molecules, including:

• development of oral GLP-1 agonists and metabolic disease therapies
• immunology and inflammation therapies
• oral biologic drug delivery programs
• endocrine and hormonal therapies
• next-generation oral medicines requiring enhanced intestinal absorption
• programs requiring scale-up-ready excipients for commercial manufacturing pathways
• designed for oral delivery and commercial scale-up

Permexa™ Sodium Caprate Mechanism of Action

Permeation enhancers and co-localization excipients for improved bioavailability and efficient material handling.

Ashland is always innovating

With continued growth in oral peptide and biologics development, Ashland is expanding its pharmaceutical excipient portfolio to support the next generation of oral drug delivery. To help customers and partners overcome formulation challenges and evolving market needs, permexa™ salcaprozate sodium (SNAC) and permexa™ sodium caprylate (C8) will be upcoming additions to the Ashland oral biologics portfolio offering.

Continue reading here

Source: Ashland, website: Who shines through biological barriers? – permexa™ sodium caprate, permexa™ sodium caprate

If you have any questions or need a sample by Ashland, please feel free to contact us: